{
  "id": "f8ce4fa0da6308b7",
  "title": "STAT+: The old Vinay Prasad never left. He just changed jobs",
  "description": "Prasad changed jobs but his conservative regulatory doctrine remains the same, particularly for cell and gene therapies. The approval bar is much higher now.",
  "content": "Prasad changed jobs but his conservative regulatory doctrine remains the same, particularly for cell and gene therapies. The approval bar is much higher now.",
  "source": "STAT",
  "source_url": "https://www.statnews.com/2026/02/12/prasad-takes-conservative-approach-rare-disease-drugs-adams-biotech-scorecard/?utm_campaign=rss",
  "published_at": "2026-02-12T11:30:00+00:00",
  "fetched_at": "2026-02-13T00:31:20.432552+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "regulatory",
    "ai"
  ],
  "location": null,
  "raw_data": {
    "title": "STAT+: The old Vinay Prasad never left. He just changed jobs",
    "description": "Prasad changed jobs but his conservative regulatory doctrine remains the same, particularly for cell and gene therapies. The approval bar is much higher now.",
    "url": "https://www.statnews.com/2026/02/12/prasad-takes-conservative-approach-rare-disease-drugs-adams-biotech-scorecard/?utm_campaign=rss",
    "published": "2026-02-12T11:30:00+00:00",
    "source": "STAT"
  }
}